Skip to main content
Autolus Therapeutics plc logo

Autolus Therapeutics plc — Investor Relations & Filings

Ticker · AUTL ISIN · US05280R1005 LEI · 549300C0KZP8EYROLL02 US Manufacturing
Open in API
Filings indexed 297 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country GB United Kingdom
Listing US AUTL

About Autolus Therapeutics plc

https://www.autolus.com/

Autolus Therapeutics plc is a commercial-stage biopharmaceutical company developing next-generation, programmed T cell therapies for cancer and autoimmune diseases. The company specializes in Chimeric Antigen Receptor (CAR) T-cell technology, which reprograms a patient's own T cells to recognize and eliminate disease cells. Its lead therapy, obecabtagene autoleucel (obe-cel), is approved for the treatment of adult relapsed/refractory B-cell Acute Lymphoblastic Leukemia (ALL). Autolus leverages its advanced cell programming capabilities and proprietary manufacturing processes to develop a pipeline of precise and controlled autologous therapies targeting hematological malignancies, solid tumors, and autoimmune conditions.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K
Report Publication Announcement Classification · 84% confidence The document is a U.S. SEC Form 8-K “Current Report” that does not itself contain the full financial results or presentation but instead “furnishes” a press release (Exhibit 99.1) announcing quarter-end results and a corporate presentation (Exhibit 99.2). It is not the substantive earnings release or presentation itself, nor is it a management discussion or interim report with full financial statements. Rather, it simply announces the publication and attaches those exhibits. This matches our definition of a Report Publication Announcement (RPA).
2026-05-14 English
8-K - Autolus Therapeutics plc (0001730463) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content describes a workforce reduction plan approved by the Board of Directors, including severance costs and operational efficiency measures. It also references a press release and financial guidance update. There are no detailed financial statements or comprehensive financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a transcript, proxy, or governance report. It is a regulatory filing reporting a significant corporate event (workforce reduction and cost restructuring). Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2026-04-29 English
8-K - Autolus Therapeutics plc (0001730463) (Filer)
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text specifically mentions Item 7.01 Regulation FD Disclosure about a virtual investor event and presentation materials posted on the company's website. The presentation is attached as Exhibit 99.1. The document explicitly states that the information is "furnished" and not "filed" for certain regulatory purposes, indicating it is an announcement rather than a full report. The content is a disclosure of an investor presentation event and the availability of presentation materials, not the presentation itself or a detailed financial report. Therefore, the document fits best into the category of Investor Presentation (IP) as it relates to a detailed presentation for investors focusing on financials, strategy, and market position, which is being disclosed via this Form 8-K filing.
2026-04-08 English
10-K - Autolus Therapeutics plc (0001730463) (Filer)
Annual Report FY 2025
2026-03-27 English
8-K - Autolus Therapeutics plc (0001730463) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 27, 2026, reporting the company's financial results for the year ended December 31, 2025, and providing a corporate update. It references a press release (Exhibit 99.1) and a corporate presentation (Exhibit 99.2) but does not contain the full financial statements or detailed financial data itself. The document is a current report announcing results and updates rather than the full annual report or earnings release. Given the nature of Form 8-K filings and the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes current reports like Form 8-K that announce events or results without full financial statements.
2026-03-27 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.